The prognostic and biology of tumour-infiltrating lymphocytes in the immunotherapy of cancer
Y Liu, Z Liu, Y Yang, J Cui, J Sun, Y Liu - British Journal of Cancer, 2023 - nature.com
Tumour immunotherapy has achieved remarkable clinical success in many different types of
cancer in the past two decades. The outcome of immune checkpoint inhibitors in cancer …
cancer in the past two decades. The outcome of immune checkpoint inhibitors in cancer …
[HTML][HTML] Chasing Uterine Cancer with NK Cell-Based Immunotherapies
V Kumar, C Bauer, JH Stewart IV - Future Pharmacology, 2022 - mdpi.com
Gynecological cancers, including endometrial adenocarcinoma, significantly contribute to
cancer incidence and mortality worldwide. The immune system plays a significant role in …
cancer incidence and mortality worldwide. The immune system plays a significant role in …
[HTML][HTML] Tumor immune microenvironment in endometrial cancer of different molecular subtypes: evidence from a retrospective observational study
Y Dai, L Zhao, D Hua, L Cui, X Zhang, N Kang… - Frontiers in …, 2022 - frontiersin.org
Objective Tumor immune microenvironmental features may predict survival and guide
treatment. This study aimed to comprehensively decipher the immunological features of …
treatment. This study aimed to comprehensively decipher the immunological features of …
[HTML][HTML] Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition
H Al-Sudani, Y Ni, P Jones, H Karakilic, L Cui… - NPJ Precision …, 2023 - nature.com
The objective was to correlate CD47 gene expression with resistance to immune checkpoint
inhibitors (ICI) in tumor tissue of gynecological cancer (GC). Further, we sought to assess the …
inhibitors (ICI) in tumor tissue of gynecological cancer (GC). Further, we sought to assess the …
[HTML][HTML] Influence of androgen deprivation therapy on the PD-L1 expression and immune activity in prostate cancer tissue
U Sommer, C Ebersbach, AMK Beier… - Frontiers in Molecular …, 2022 - frontiersin.org
Immune checkpoint inhibitors have become a promising new therapy for cancer treatment.
However, due to prostate cancer's high heterogeneity and immune-suppressive tumour …
However, due to prostate cancer's high heterogeneity and immune-suppressive tumour …
[HTML][HTML] The biological roles of CD47 in ovarian cancer progression
L Xing, Z Wang, Y Feng, H Luo, G Dai, L Sang… - Cancer Immunology …, 2024 - Springer
Ovarian cancer is one of the most lethal malignant tumors, characterized by high incidence
and poor prognosis. Patients relapse occurred in 65–80% after initial treatment. To date, no …
and poor prognosis. Patients relapse occurred in 65–80% after initial treatment. To date, no …
Immunotherapy with IL12 and PD1/CTLA4 inhibition is effective in advanced ovarian cancer and associates with reversal of myeloid cell-induced immunosuppression
PG Pavicic Jr, PA Rayman, S Swaidani… - …, 2023 - Taylor & Francis
The tumor microenvironment (TME) in ovarian cancer (OC) is characterized by immune
suppression, due to an abundance of suppressive immune cells populations. To effectively …
suppression, due to an abundance of suppressive immune cells populations. To effectively …
[HTML][HTML] The role of interferons in ovarian cancer progression: Hinderer or promoter?
T Liu, Y Li, X Wang, X Yang, Y Fu, Y Zheng… - Frontiers in …, 2022 - frontiersin.org
Ovarian cancer (OC) is a common gynecologic malignancy with poor prognosis and high
mortality. Changes in the OC microenvironment are closely related to the genesis, invasion …
mortality. Changes in the OC microenvironment are closely related to the genesis, invasion …
Potential Roles of Infiltrated Immune Cells in the Tumour Microenvironment of Endometrial Cancer
J Blemings-Derrick, DA Zinovkin, MZI Pranjol - 2022 - Springer
Many innate and adaptive immune cells are present in endometrial cancer (EC) and play
key roles in the tumour microenvironment (TME); through initiation, stimulation, and …
key roles in the tumour microenvironment (TME); through initiation, stimulation, and …
[PDF][PDF] A risk model based on the tumor microenvironment to predict survival and immunotherapy efficacy for ovarian cancer.
YR Wang, WL Wu, X Cheng, HX Gao… - European Review for …, 2023 - europeanreview.org
OBJECTIVE: Based on the interactions between immune components in the tumor
microenvironment and ovarian cancer (OC) cells, immunotherapies have been …
microenvironment and ovarian cancer (OC) cells, immunotherapies have been …